BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 21685829)

  • 1. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
    Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan.
    Yang SL; Lin TW; Lin HC; Wang HY; Chang PY; Wang PN; Yang S; Lu JJ
    J Microbiol Immunol Infect; 2021 Oct; 54(5):971-978. PubMed ID: 33632621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
    Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
    Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Cintra-Cabrera M; Suárez-Benjumea A; Bernal-Blanco G; González-Roncero FM; Toapanta-Gaibor NG; Súñer-Poblet M; Pérez-Valdivia MÁ; Fernández-Cuenca F; Gentil-Govantes MÁ; Rocha-Castilla JL
    Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.